London’s Alternatives Investment Marketplace (AIM) grew by 33 companies in 2021, its biggest increase since 2007.

City AM has reported 66 companies floated on the marketplace last year in the best year for IPOs since 2014, according to data analysed by accountancy firm UHY Hacker Young. AIM now has a market cap of approximately £150bn, up from £85bn five years ago, with a total of 852 companies listed.

Here are some of the IPO's VOX Markets covered during the period;

Revolution Beauty REVB  is a global mass beauty and personal care business which operates a multi brand, multi category strategy and sells its products both DTC via its e-commerce operations, and in both physical and digital retailers through wholesale relationships. Today, the Group has products sold through a retail footprint of c.11,000 doors across leading retail chains in the UK, USA and other international markets. This is complemented by a fast-growing digital business including its DTC website and an increasing number of global digital partners. The Group is recognised as one of the fastest product innovators in the accessible beauty market, and is challenging the established order by rapidly developing and launching new products to take advantage of new market trends, promoting brand awareness via influencer marketing, its own social media following and by providing high quality products at prices substantially lower than beauty prestige competitors. 

 

Belluscura BELL is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. The Company's innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations. Using patented oxygen enrichment technology, their mission is to help improve the quality of life for millions of people around the world. 

 

Trellus Health (TRLS) is a leading pioneer in resilience-driven care and the first digital health company focused on the intersection of chronic physical conditions and mental health. Trellus Health's digital-first chronic care management solution integrates convenient access to a licensed multidisciplinary care team with a suite of tools for resilience assessment, education and behavior modification, remote monitoring, health maintenance and prevention. Through its TrellusElevate™ connected care platform and companion App, the company enables coordination and delivery of expert whole-person care, addressing both clinical and behavioral health together, in context, to improve outcomes and reduce healthcare costs for patients, employers, and the healthcare system. Trellus Health is commercialising the provision of digital chronic condition management solutions for employers and health plans that utilise the scientifically validated resilience-based methodology and a proprietary HIPAA-compliant technology platform called TrellusElevate™ to coordinate and deliver personalised care remotely via telehealth. The Company is initially focused on Inflammatory bowel disease ("IBD"), which includes the chronic incurable conditions of Crohn's Disease and ulcerative colitis, but considers its approach to have potential utility and demand across many chronic conditions.  A direct-to-consumer (DTC) offering is also being devised for IBD, allowing patients to pay directly or submit claims for insurance reimbursement utilising existing procedural codes. 

 

LungLife (LLAI) is a developer of clinical diagnostic solutions enhanced by artificial intelligence for lung cancer, which is the number one cancer killer. The Company’s diagnostic solutions are designed to make a significant impact in the early detection of lung cancer. LungLife's IP and technology is a combination of the recovery of rare cells and blood-based biomarkers shown to be altered in lung cancer. The Company employs advanced machine learning to improve biomarker detection, and intends to build a deep, novel pool of lung cancer-related data for AI-enabled applications designed to improve its diagnostic solutions over time.